Medical Device Nonvisual Accessibility Act of 2025
HB5605, the Medical Device Nonvisual Accessibility Act of 2025, would amend the Federal Food, Drug, and Cosmetic Act to require certain medical devices with digital user interfaces to meet nonvisual accessibility standards. The bill is aimed at making covered devices usable by blind and low-vision individuals with comparable privacy, independence, and ease of use as for other users. It focuses on devices such as class II and III medical devices that are cleared, authorized, or approved after the bill’s effective date and that are intended for home use rather than solely for health care provider settings.
The bill directs the Secretary of Health and Human Services to develop the accessibility standard, consult with the Architectural and Transportation Barriers Compliance Board and blind/low-vision stakeholders, provide manufacturer training, and issue proposed and final regulations on a set timeline. It also allows the Secretary to grant waivers if compliance would fundamentally alter the device or impose an undue hardship on the manufacturer. A covered device that does not meet the standard, and is not waived, would be treated as adulterated under the FDCA, creating a compliance obligation for manufacturers and a potential enforcement mechanism for FDA.
If enacted, the bill would add a new accessibility requirement to the Federal Food, Drug, and Cosmetic Act for certain medical devices with screens or mobile-app interfaces. It would create a new section 515D and amend section 501 to deem noncompliant covered devices adulterated after the rule’s effective date, thereby affecting FDA review, manufacturer design practices, and post-market compliance for home-use digital medical devices. The measure would primarily affect manufacturers of class II and III devices with user interfaces, while excluding devices intended solely for professional or non-home settings.
Based on the bill text and sponsorship, the overall sentiment appears strongly supportive and bipartisan in intent, with the bill framed as a disability-access and patient-safety measure. The findings emphasize independence, privacy, and safety for blind and low-vision users, and the inclusion of multiple sponsors from both parties suggests broad interest in the issue. No committee debate or vote history is provided, so there is no recorded opposition in the available materials.
The main points of potential contention are the compliance burden on manufacturers and the scope of the accessibility mandate. The bill anticipates these concerns by allowing waivers for fundamental alteration or undue hardship, but manufacturers may still object to added design, testing, training, and regulatory costs, especially for devices with complex interfaces. Accessibility advocates, by contrast, are likely to favor a strong standard and may scrutinize how broadly FDA interprets waiver authority and whether the final regulations truly ensure equal access for blind and low-vision users.